On April 28, 2021 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), reported that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021 (Press release, Arbutus Biopharma, APR 28, 2021, View Source [SID1234578661]). The schedule for the press release and conference call/webcast are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

•1Q/2021 Press Release: Wednesday, May 5, 2021 at 7:30 a.m. ET
•1Q/2021 Conference Call/Webcast: Wednesday, May 5, 2021 at 8:45 a.m. ET
•Domestic Dial-In Number: (866) 393-1607
•International Dial-In Number: (914) 495-8556
•Conference ID Number: 4445858
A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com or directly at Live Webcast.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4445858.